DC Advisory advises Arlington Capital Partners and its portfolio company, Riverpoint Medical on the acquisition of CP Medical
Background
- Riverpoint Medical (Riverpoint) is a leading developer, designer and manufacturer of medical devices, focused on advanced surgical fiber and regenerative technologies
- Riverpoint’s offering includes implants, high strength fiber solutions, and proprietary surgical coatings for the sports medicine, orthopedic, wound closure, and cardiovascular markets
- Riverpoint is a portfolio company of Arlington Capital Partners (Arlington), a Washington, DC-area-based private equity firm with $8 billion+ in AUM. Arlington is focused on middle market investment opportunities in industries such as Healthcare, Aerospace & Defense, Government Services & Technology, and Business Services & Software
- For over 20 years, CP Medical has been a leading device manufacturer focused on specialty surgical applications and wound closure products for the surgical and animal health markets
Process
- DC Advisory was exclusively engaged to advise Arlington and its portfolio company, Riverpoint on the acquisition of CP Medical
Outcome
- CP Medical brings a portfolio of specialty surgical and animal health wound closure devices, including resorbable and non-absorbable products, which are complementary to Riverpoint’s existing capabilities and offerings
- Riverpoint’s product development and engineering resources also broaden CP Medical’s existing product portfolio
- This transaction demonstrates DC Advisory’s deep sector expertise and strengthens its existing credentials in the Healthcare sector
What to read next
Date
Sectors
- Healthcare
Deal type
- M&A Advisory
Deal locations
Deal team
Managing Director
Vice President
Actions
Disclaimer
For more information, please see our transaction disclaimer
For important information regarding testimonials, please see our disclaimer.